Compare Delta Air Lines, Inc. (DAL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Mesoblast Limited — how do they compare? Delta Air Lines, Inc. trades at $82.17 (market cap $54.02B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Delta Air Lines, Inc. is far larger — about 30.9× Mesoblast Limited's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Mesoblast Limited for 15 Days on average.
| DAL | MESO | |
|---|---|---|
Market Cap | $54.02B | $1.75B |
Volume | 9,632,845 | 239,027 |
Sector | Industrials | Health |
52-Week High | $93.66 | $20.96 |
52-Week Low | $55.65 | $13.19 |
Typical Hold Time | 97 Days | 15 Days |
Enterprise Value | $69.34B | $1.83B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.0% for the day, with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with a P/E of 13.62 and net income margin of 5.78%, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American Airlines' customer poaching efforts and Elon Musk's criticism over Delta's Wi-Fi provider choice.
DAL presents a compelling value opportunity with 82% analyst buy ratings and a $103.36 consensus target, offering 26% upside. However, risks include fuel cost volatility, competitive threats to premium customers, and recent earnings miss. The stock's current technical weakness may provide entry points for long-term investors focused on the company's strong cash flow generation and improving balance sheet.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
